<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Huntington&#39;s Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Huntington&#39;s Disease</span>
        </nav>

        <header class="page-header">
            <h1>Huntington&#39;s Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007739" target="_blank">
                        MONDO:0007739
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurodegenerative Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Movement Disorder</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">nervous system disorder</span>
                    
                    <span class="tag tag-classification">neurodegenerative disease</span>
                    
                    <span class="tag tag-classification">movement disorder</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">üë™</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal Dominant
                    
                </div>
                
                
    
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29325616" target="_blank">PMID:29325616</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington disease is a monogenic neurodegenerative disorder that displays an autosomal-dominant pattern of inheritance."</div>
                
                
                <div class="evidence-explanation">The literature explicitly states that Huntington&#39;s disease follows an autosomal-dominant pattern of inheritance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28803251" target="_blank">PMID:28803251</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of CAG triplet repeat."</div>
                
                
                <div class="evidence-explanation">The literature confirms that Huntington&#39;s disease is an autosomal dominant disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36352624" target="_blank">PMID:36352624</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s Disease (HD) is an autosomal dominant, progressive neuropsychiatric illness caused by CAG repeat expansion."</div>
                
                
                <div class="evidence-explanation">The literature supports that Huntington&#39;s disease is inherited in an autosomal dominant manner.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Juvenile Huntington&#39;s Disease
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26557176" target="_blank">PMID:26557176</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions."</div>
                
                
                <div class="evidence-explanation">The abstract describes a case of childhood-onset Huntington&#39;s disease that progresses rapidly, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36318082" target="_blank">PMID:36318082</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Juvenile-onset Huntington&#39;s disease (JOHD) is a rare form of Huntington&#39;s disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that Juvenile Huntington&#39;s Disease is rare, begins early, and progresses rapidly, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14584235" target="_blank">PMID:14584235</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The presentation of juvenile Huntington&#39;s disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed."</div>
                
                
                <div class="evidence-explanation">The abstract acknowledges the existence of juvenile Huntington&#39;s disease, which supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Late-Onset Huntington&#39;s Disease
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Typically begins after the age of 50 and may have a slower progression.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28671137" target="_blank">PMID:28671137</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Although the typical age of onset for Huntington&#39;s disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."</div>
                
                
                <div class="evidence-explanation">The statement that Huntington&#39;s Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington&#39;s Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17390259" target="_blank">PMID:17390259</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."</div>
                
                
                <div class="evidence-explanation">This reference refutes the statement that Huntington&#39;s Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36318082" target="_blank">PMID:36318082</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Juvenile-onset Huntington&#39;s disease (JOHD) is a rare form of Huntington&#39;s disease (HD) characterized by symptom onset before the age of 21 years."</div>
                
                
                <div class="evidence-explanation">This reference discusses Juvenile-onset Huntington&#39;s Disease, which is not relevant to the claim about typical onset after the age of 50.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">CAG Repeat Expansion in the HTT Gene</div>
                
                <div class="item-desc">Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        DNA mismatch repair
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006298" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        cerebral cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7620118" target="_blank">PMID:7620118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms..."</div>
                
                
                <div class="evidence-explanation">The reference confirms that an expanded CAG repeat in the HTT gene is the cause of Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35395060" target="_blank">PMID:35395060</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is caused by an expansion of the CAG trinucleotide repeat domain in the huntingtin gene that results in expression of a mutant huntingtin protein (mHTT) containing an expanded polyglutamine tract in the amino terminus."</div>
                
                
                <div class="evidence-explanation">The literature clearly states that HD is caused by an expanded CAG repeat in the HTT gene, leading to a mutant huntingtin protein with an abnormal polyglutamine tract.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27529325" target="_blank">PMID:27529325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) belongs to the group of inherited polyglutamine (PolyQ) diseases caused by an expanded CAG repeat in the coding region of the Huntingtin (HTT) gene that results in an elongated polyQ stretch."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by specifying that HD is caused by an expanded CAG repeat in the HTT gene, leading to an elongated polyglutamine stretch.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mutant Huntingtin Protein Aggregation</div>
                
                <div class="item-desc">Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        medium spiny neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_1001474" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein aggregation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070841" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        cerebral cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35319359" target="_blank">PMID:35319359</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenesis of HD involves cleavage of the huntingtin protein followed by the neuronal accumulation of its aggregated form."</div>
                
                
                <div class="evidence-explanation">The literature supports that the pathogenesis of Huntington&#39;s Disease involves the accumulation of aggregated mutant huntingtin protein, leading to neuronal dysfunction and death.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12657365" target="_blank">PMID:12657365</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The initial and primary target of degeneration in HD is the striatal medium spiny GABAergic neuron, and by end stages of the disease up to 95% of these neurons are lost."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by highlighting the primary degeneration of neurons in the striatum due to Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31813995" target="_blank">PMID:31813995</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutant HTT (mHTT) toxicity is caused by its aggregation/oligomerization. The striatum is the most vulnerable region, although all brain regions undergo neuronal degeneration in the disease."</div>
                
                
                <div class="evidence-explanation">This literature supports the statement by confirming that mutant huntingtin protein aggregation leads to neurotoxicity, particularly in the striatum.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Excitotoxicity</div>
                
                <div class="item-desc">Overactivation of glutamate receptors leading to neuronal damage.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        medium spiny neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_1001474" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        chemical synaptic transmission
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007268" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        excitatory postsynaptic potential
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060079" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38776957" target="_blank">PMID:38776957</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD."</div>
                
                
                <div class="evidence-explanation">The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1464368" target="_blank">PMID:1464368</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases."</div>
                
                
                <div class="evidence-explanation">This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7590394" target="_blank">PMID:7590394</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA."</div>
                
                
                <div class="evidence-explanation">The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mitochondrial Dysfunction</div>
                
                <div class="item-desc">Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        medium spiny neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_1001474" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        oxidative phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006119" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        mitochondrion organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007005" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        cerebral cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuroinflammation</div>
                
                <div class="item-desc">Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        microglial cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001774" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">D2 Receptor Medium Spiny Neuron Selective Vulnerability</div>
                
                <div class="item-desc">D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        medium spiny neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_1001474" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein aggregation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070841" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        synaptic transmission
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007268" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(5)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Growth<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dysphagia
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002015" target="_blank">
                                Dysphagia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002015)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">5</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chorea
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002072" target="_blank">
                                Chorea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002072)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24176425" target="_blank">PMID:24176425</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington disease (HD) is an autosomal dominant, adult-onset, progressive neurodegenerative disease characterized by the triad of abnormal movements (typically chorea), cognitive impairment, and psychiatric problems."</div>
                
                
                <div class="evidence-explanation">The reference clearly states that chorea is a characteristic abnormal movement in Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36049455" target="_blank">PMID:36049455</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Chorea is one of the major manifestations of Huntington&#39;s disease."</div>
                
                
                <div class="evidence-explanation">This reference confirms that chorea is a major manifestation of Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31707371" target="_blank">PMID:31707371</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Anosognosia, or unawareness of illness of deficits, has been observed in Huntington&#39;s disease (HD) in relation to motor and cognitive signs and symptoms. Most studies of awareness in HD have used self-report questionnaire methodology rather than asking patients to report on their..."</div>
                
                
                <div class="evidence-explanation">The reference mentions chorea in the context of Huntington&#39;s Disease, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dystonia
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001332" target="_blank">
                                Dystonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001332)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Bradykinesia
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002067" target="_blank">
                                Bradykinesia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002067)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cognitive Impairment
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100543" target="_blank">
                                Cognitive impairment
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100543)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Depression
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000716" target="_blank">
                                Depression
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000716)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Weight Loss
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                                Weight loss
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001824)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">13</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HTT
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic CAG Repeat Expansion)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (10 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27188817" target="_blank">PMID:27188817</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington disease is devastating to patients and their families - with autosomal dominant inheritance... The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin."</div>
                
                
                <div class="evidence-explanation">The literature explicitly states that Huntington&#39;s disease is caused by an expanded CAG trinucleotide repeat in the HTT gene and is inherited in an autosomal dominant manner.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33579864" target="_blank">PMID:33579864</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of the HTT CAG repeat."</div>
                
                
                <div class="evidence-explanation">This reference confirms that Huntington&#39;s disease is caused by the expansion of the HTT CAG repeat and follows an autosomal dominant inheritance pattern.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31820322" target="_blank">PMID:31820322</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene."</div>
                
                
                <div class="evidence-explanation">This source supports the statement by indicating that Huntington&#39;s disease is an autosomal dominant disorder caused by a CAG expansion in the HTT gene.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 7 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MSH3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MLH1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PMS1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PMS2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    LIG1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Genetic Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PPARGC1A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SLC1A2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BDNF
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NTRK2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DRD1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DRD2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SQSTM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathophysiological Role)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tetrabenazine
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to manage chorea by depleting dopamine.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24366610" target="_blank">PMID:24366610</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects."</div>
                
                
                <div class="evidence-explanation">This reference confirms that tetrabenazine is used to manage chorea in Huntington&#39;s Disease by depleting dopamine.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20869622" target="_blank">PMID:20869622</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington&#39;s disease."</div>
                
                
                <div class="evidence-explanation">This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20442355" target="_blank">PMID:20442355</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion."</div>
                
                
                <div class="evidence-explanation">This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington&#39;s Disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antipsychotic Medications
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used for psychiatric symptoms like irritability and agitation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27534434" target="_blank">PMID:27534434</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."</div>
                
                
                <div class="evidence-explanation">The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16383221" target="_blank">PMID:16383221</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."</div>
                
                
                <div class="evidence-explanation">The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36496108" target="_blank">PMID:36496108</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington&#39;s disease..."</div>
                
                
                <div class="evidence-explanation">Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington&#39;s Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Selective Serotonin Reuptake Inhibitors (SSRIs)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to manage depression.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18394562" target="_blank">PMID:18394562</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22119091" target="_blank">PMID:22119091</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."</div>
                
                
                <div class="evidence-explanation">The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington&#39;s Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Physical Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Helps maintain mobility and function.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31907286" target="_blank">PMID:31907286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD."</div>
                
                
                <div class="evidence-explanation">The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington&#39;s Disease, supporting the statement that physical therapy helps maintain mobility and function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31177235" target="_blank">PMID:31177235</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Prior Huntington&#39;&#39;s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life."</div>
                
                
                <div class="evidence-explanation">The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25062860" target="_blank">PMID:25062860</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures."</div>
                
                
                <div class="evidence-explanation">The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Speech Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000077" target="_blank">
                            MAXO:0000077
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Helps manage dysarthria and dysphagia.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28983422" target="_blank">PMID:28983422</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"SLPs play an important role in the evaluation and management of dysarthria and dysphagia."</div>
                
                
                <div class="evidence-explanation">The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington&#39;s Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33577706" target="_blank">PMID:33577706</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group."</div>
                
                
                <div class="evidence-explanation">The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31989345" target="_blank">PMID:31989345</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature."</div>
                
                
                <div class="evidence-explanation">The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Occupational Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Assists with daily living activities.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28947114" target="_blank">PMID:28947114</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression."</div>
                
                
                <div class="evidence-explanation">The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36055643" target="_blank">PMID:36055643</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders."</div>
                
                
                <div class="evidence-explanation">This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31177235" target="_blank">PMID:31177235</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Prior Huntington&#39;s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">None Applicable</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (10 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20591965" target="_blank">PMID:20591965</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease."</div>
                
                
                <div class="evidence-explanation">The provided reference does not mention anything about &#39;None Applicable&#39; in relation to Huntington&#39;s Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1535663" target="_blank">PMID:1535663</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"What ethical justification can be found for informing a person that he or she will later develop a lethal disease for which no therapy is available?"</div>
                
                
                <div class="evidence-explanation">The provided reference discusses the ethics of genetic prediction and testing for Huntington&#39;s Disease but does not mention &#39;None Applicable&#39; as a value.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29856024" target="_blank">PMID:29856024</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Huntington&#39;s disease (HD) is a monogenic, autosomal dominant inherited fatal disease that affects 1 in 10,000 people worldwide."</div>
                
                
                <div class="evidence-explanation">The provided reference discusses nonhuman primate models for Huntington&#39;s Disease but does not mention &#39;None Applicable&#39; as a value.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 7 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Elevated Neuronal Inclusions
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22200539" target="_blank">PMID:22200539</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs)."</div>
                
                
                <div class="evidence-explanation">The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38810948" target="_blank">PMID:38810948</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients."</div>
                
                
                <div class="evidence-explanation">The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19172113" target="_blank">PMID:19172113</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species."</div>
                
                
                <div class="evidence-explanation">The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Huntington&#39;s Disease
category: Genetic
parents:
- Neurodegenerative Disorder
- Movement Disorder
synonyms:
- Huntington&#39;s Chorea
has_subtypes:
- name: Juvenile Huntington&#39;s Disease
  description: A rare, early-onset form that begins in childhood or adolescence and
    progresses more rapidly than typical forms.
  evidence:
  - reference: PMID:26557176
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is a rare dominantly inherited neurodegenerative
      disorder... As is expected in a case of childhood-onset HD, our patient is rapidly
      deteriorating and is currently in the terminal phase of his illness along with
      resistant convulsions.
    explanation: The abstract describes a case of childhood-onset Huntington&#39;s disease
      that progresses rapidly, supporting the statement.
  - reference: PMID:36318082
    supports: SUPPORT
    snippet: Juvenile-onset Huntington&#39;s disease (JOHD) is a rare form of Huntington&#39;s
      disease (HD) characterized by symptom onset before the age of 21 years... The
      mean annualized decrease in striatal volume in the JOHD group was -3.99% compared
      to -0.06% in the GNE.
    explanation: The abstract confirms that Juvenile Huntington&#39;s Disease is rare,
      begins early, and progresses rapidly, supporting the statement.
  - reference: PMID:14584235
    supports: SUPPORT
    snippet: The presentation of juvenile Huntington&#39;s disease can cause diagnostic
      difficulties. The genetics and pathogenesis of the condition are discussed.
    explanation: The abstract acknowledges the existence of juvenile Huntington&#39;s
      disease, which supports the statement.
  - reference: PMID:2942452
    supports: SUPPORT
    snippet: Of 195 cases of juvenile Huntington disease gathered from case descriptions...
      It is argued that juvenile Huntington disease should not be regarded as a separate
      clinical entity, but as a manifestation of the rigid variant of the disease.
    explanation: The abstract discusses juvenile Huntington&#39;s disease and its characteristics,
      supporting the statement.
- name: Late-Onset Huntington&#39;s Disease
  description: Typically begins after the age of 50 and may have a slower progression.
  evidence:
  - reference: PMID:28671137
    supports: PARTIAL
    snippet: &#39;BACKGROUND: Although the typical age of onset for Huntington&#39;&#39;s disease
      (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have
      a late onset (over 60 years of age).&#39;
    explanation: The statement that Huntington&#39;s Disease typically begins after the
      age of 50 is not entirely accurate. While late-onset Huntington&#39;s Disease (LoHD)
      does occur, the typical age of onset for HD is in the fourth decade. However,
      the statement is partially supported by the fact that some individuals do experience
      late onset, and LoHD may have a slower progression.
  - reference: PMID:17390259
    supports: REFUTE
    snippet: Huntington&#39;s disease may present at any age, but most typically manifests
      between the ages of 35 and 45 years as a slowly progressive neurodegenerative
      movement disorder with cognitive and behavioral impairment.
    explanation: This reference refutes the statement that Huntington&#39;s Disease typically
      begins after the age of 50. It states that HD most typically manifests between
      the ages of 35 and 45 years.
  - reference: PMID:36318082
    supports: NO_EVIDENCE
    snippet: Juvenile-onset Huntington&#39;s disease (JOHD) is a rare form of Huntington&#39;s
      disease (HD) characterized by symptom onset before the age of 21 years.
    explanation: This reference discusses Juvenile-onset Huntington&#39;s Disease, which
      is not relevant to the claim about typical onset after the age of 50.
  - reference: PMID:28087720
    supports: NO_EVIDENCE
    snippet: Following predictive testing for Huntington disease (HD), knowledge of
      one&#39;s carrier status may have consequences on disease onset.
    explanation: This reference does not provide information relevant to the typical
      age of onset or progression of Huntington&#39;s Disease.
prevalence:
- population: Global
  percentage: 0.004-0.01
  evidence:
  - reference: PMID:1535611
    supports: PARTIAL
    snippet: It is concluded that most European populations, both Northern and Southern,
      show a relatively high prevalence (4-8 per 100,000), and that the disorder may
      also be frequent in India and parts of central Asia. HD is notably rare in Finland
      and in Japan, but data for Eastern Asia and Africa are inadequate.
    explanation: The prevalence of Huntington&#39;s Disease varies significantly across
      different regions, with some populations showing higher prevalence and others
      showing lower. Therefore, a global percentage of 0.004-0.01 may not accurately
      reflect the variability seen in different regions.
  - reference: PMID:28671137
    supports: NO_EVIDENCE
    snippet: Although the typical age of onset for Huntington&#39;s disease (HD) is in
      the fourth decade, between 4.4-11.5% of individuals with HD have a late onset
      (over 60 years of age).
    explanation: This reference discusses the age of onset and not the global prevalence.
inheritance:
- name: Autosomal Dominant
  evidence:
  - reference: PMID:29325616
    supports: SUPPORT
    snippet: Huntington disease is a monogenic neurodegenerative disorder that displays
      an autosomal-dominant pattern of inheritance.
    explanation: The literature explicitly states that Huntington&#39;s disease follows
      an autosomal-dominant pattern of inheritance.
  - reference: PMID:28803251
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is an autosomal dominant neurodegenerative
      disorder caused by the abnormal expansion of CAG triplet repeat.
    explanation: The literature confirms that Huntington&#39;s disease is an autosomal
      dominant disorder.
  - reference: PMID:36352624
    supports: SUPPORT
    snippet: Huntington&#39;s Disease (HD) is an autosomal dominant, progressive neuropsychiatric
      illness caused by CAG repeat expansion.
    explanation: The literature supports that Huntington&#39;s disease is inherited in
      an autosomal dominant manner.
pathophysiology:
- name: CAG Repeat Expansion in the HTT Gene
  description: Mutation characterized by an expanded number of CAG repeats, which
    encodes an abnormal polyglutamine tract in the huntingtin protein.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  biological_processes:
  - preferred_term: DNA mismatch repair
    term:
      id: GO:0006298
      label: mismatch repair
  evidence:
  - reference: PMID:7620118
    supports: SUPPORT
    snippet: Early in 1993, an unstable, expanded trinucleotide repeat in a novel
      gene of unknown function was identified on HD chromosomes. This discovery unleased
      a flurry of experimentation that has established the expanded CAG repeat the
      almost universal cause of the characteristic neurologic symptoms and pathology
      of this neurodegenerative disorder of midlife onset.
    explanation: The reference confirms that an expanded CAG repeat in the HTT gene
      is the cause of Huntington&#39;s Disease.
  - reference: PMID:35395060
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is caused by an expansion of the CAG trinucleotide
      repeat domain in the huntingtin gene that results in expression of a mutant
      huntingtin protein (mHTT) containing an expanded polyglutamine tract in the
      amino terminus.
    explanation: The literature clearly states that HD is caused by an expanded CAG
      repeat in the HTT gene, leading to a mutant huntingtin protein with an abnormal
      polyglutamine tract.
  - reference: PMID:27529325
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) belongs to the group of inherited polyglutamine
      (PolyQ) diseases caused by an expanded CAG repeat in the coding region of the
      Huntingtin (HTT) gene that results in an elongated polyQ stretch.
    explanation: This reference supports the statement by specifying that HD is caused
      by an expanded CAG repeat in the HTT gene, leading to an elongated polyglutamine
      stretch.
  - reference: PMID:33579866
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) (OMIM 143100) is caused by an expanded CAG
      repeat tract in the HTT gene.
    explanation: The reference supports the statement, confirming that HD is caused
      by an expanded CAG repeat in the HTT gene.
  - reference: PMID:31398342
    supports: SUPPORT
    snippet: Variable, glutamine-encoding, CAA interruptions indicate that a property
      of the uninterrupted HTT CAG repeat sequence, distinct from the length of huntingtin&#39;s
      polyglutamine segment, dictates the rate at which Huntington&#39;s disease (HD)
      develops.
    explanation: This reference supports the statement by discussing the role of uninterrupted
      CAG repeats in the HTT gene in the development of HD.
- name: Mutant Huntingtin Protein Aggregation
  description: Aggregates of mutant huntingtin protein lead to neuronal dysfunction
    and death, particularly in the striatum and cerebral cortex.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:35319359
    supports: SUPPORT
    snippet: Pathogenesis of HD involves cleavage of the huntingtin protein followed
      by the neuronal accumulation of its aggregated form.
    explanation: The literature supports that the pathogenesis of Huntington&#39;s Disease
      involves the accumulation of aggregated mutant huntingtin protein, leading to
      neuronal dysfunction and death.
  - reference: PMID:12657365
    supports: SUPPORT
    snippet: The initial and primary target of degeneration in HD is the striatal
      medium spiny GABAergic neuron, and by end stages of the disease up to 95% of
      these neurons are lost.
    explanation: This reference supports the statement by highlighting the primary
      degeneration of neurons in the striatum due to Huntington&#39;s Disease.
  - reference: PMID:31813995
    supports: SUPPORT
    snippet: Mutant HTT (mHTT) toxicity is caused by its aggregation/oligomerization.
      The striatum is the most vulnerable region, although all brain regions undergo
      neuronal degeneration in the disease.
    explanation: This literature supports the statement by confirming that mutant
      huntingtin protein aggregation leads to neurotoxicity, particularly in the striatum.
  - reference: PMID:23423362
    supports: SUPPORT
    snippet: Evaluation of postmortem HD tissue indicates that the most prominent
      cell loss occurs in cerebral cortex and striatum, forebrain regions in which
      cortical pyramidal neurons (CPNs) and striatal medium spiny neurons (MSNs) are
      the most affected.
    explanation: This reference supports the statement by indicating significant neuronal
      loss in the striatum and cerebral cortex in Huntington&#39;s Disease.
  - reference: PMID:24048953
    supports: SUPPORT
    snippet: Huntington&#39;s disease is caused by the expansion of a polyglutamine repeat
      (&gt;37 glutamines) in the disease protein huntingtin, which results in preferential
      neuronal loss in distinct brain regions.
    explanation: The literature supports the statement by confirming that mutant huntingtin
      protein causes neuronal loss in specific brain regions, including the striatum
      and cerebral cortex.
- name: Excitotoxicity
  description: Overactivation of glutamate receptors leading to neuronal damage.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: excitatory postsynaptic potential
    term:
      id: GO:0060079
      label: excitatory postsynaptic potential
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38776957
    supports: SUPPORT
    snippet: We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate
      (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
      kainate receptors in medium spiny neurons, the cell type preferentially lost
      early in HD.
    explanation: The study identifies upregulation of glutamate receptors in medium
      spiny neurons, supporting the idea of excitotoxicity due to overactivation of
      these receptors leading to neuronal damage.
  - reference: PMID:1464368
    supports: SUPPORT
    snippet: Excitotoxicity refers to neuronal cell death caused by activation of
      excitatory amino acid receptors. A substantial body of evidence has implicated
      excitotoxicity as a mechanism of cell death in both acute and chronic neurologic
      diseases.
    explanation: This reference explains the concept of excitotoxicity and supports
      the idea that overactivation of glutamate receptors can lead to neuronal damage.
  - reference: PMID:7590394
    supports: SUPPORT
    snippet: Our results indicated that elevated glutamate concentrations (15 mM,
      1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly
      increased both the concentrations of 2,3 and 2,5 DHBA.
    explanation: The study provides direct evidence that elevated glutamate levels
      increase the formation of hydroxyl radicals, implying oxidative stress induced
      by excitotoxicity, which supports the statement.
  - reference: PMID:19805493
    supports: SUPPORT
    snippet: Induction of striatal excitotoxicity in CB(2) receptor-deficient mice
      by quinolinic acid administration exacerbated brain oedema, microglial activation,
      proinflammatory-mediator state and medium-sized spiny neuron degeneration.
    explanation: This study shows that excitotoxicity induced in the striatum leads
      to medium spiny neuron degeneration, supporting the idea of excitotoxicity causing
      neuronal damage in Huntington&#39;s Disease.
- name: Mitochondrial Dysfunction
  description: Reduced efficiency of oxidative phosphorylation complexes, loss of
    mitochondrial membrane potential, and impaired mitochondrial DNA stability leading
    to bioenergetic failure.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
- name: Neuroinflammation
  description: Activation of microglia and astrocytes with neuroinflammatory responses
    occurring early in disease progression, contributing to neurodegeneration.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
- name: D2 Receptor Medium Spiny Neuron Selective Vulnerability
  description: D2 receptor-expressing medium spiny neurons show earlier huntingtin
    aggregation and greater sensitivity to CAG somatic instability compared to D1
    receptor-expressing neurons.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
phenotypes:
- name: Chorea
  evidence:
  - reference: PMID:24176425
    supports: SUPPORT
    snippet: Huntington disease (HD) is an autosomal dominant, adult-onset, progressive
      neurodegenerative disease characterized by the triad of abnormal movements (typically
      chorea), cognitive impairment, and psychiatric problems.
    explanation: The reference clearly states that chorea is a characteristic abnormal
      movement in Huntington&#39;s Disease.
  - reference: PMID:36049455
    supports: SUPPORT
    snippet: Chorea is one of the major manifestations of Huntington&#39;s disease.
    explanation: This reference confirms that chorea is a major manifestation of Huntington&#39;s
      Disease.
  - reference: PMID:31707371
    supports: SUPPORT
    snippet: &#39;BACKGROUND: Anosognosia, or unawareness of illness of deficits, has
      been observed in Huntington&#39;&#39;s disease (HD) in relation to motor and cognitive
      signs and symptoms. Most studies of awareness in HD have used self-report questionnaire
      methodology rather than asking patients to report on their symptoms in real-time.
      The two studies in which patients were asked about their chorea in real-time
      had small sample sizes and only examined patients early in disease progression.&#39;
    explanation: The reference mentions chorea in the context of Huntington&#39;s Disease,
      supporting the statement.
  - reference: PMID:6446233
    supports: SUPPORT
    snippet: Huntington&#39;s disease (chorea) is characterized by abnormal movements
      and dementia.
    explanation: This reference directly associates Huntington&#39;s Disease with chorea.
  - reference: PMID:32699773
    supports: SUPPORT
    snippet: Huntington&#39;s Disease (HD) is an autosomal dominant neurodegenerative
      disorder with a progressive decline in cognitive, motor, and psychological function.
      Chorea tends to be the most common associated movement disorder, although other
      variants of several abnormal movements are also seen.
    explanation: The reference states that chorea is the most common associated movement
      disorder in Huntington&#39;s Disease.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
- name: Dystonia
  description: Involuntary muscle contractions causing twisting and repetitive movements
    or abnormal postures.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
- name: Bradykinesia
  description: Slowness of movement, a common motor symptom in Huntington&#39;s Disease.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
- name: Cognitive Impairment
  description: Progressive decline in cognitive function affecting memory, executive
    function, and other cognitive domains.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- name: Depression
  description: Mood disorder characterized by persistent sadness and loss of interest,
    common psychiatric manifestation in HD.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- name: Weight Loss
  description: Progressive unintentional weight loss due to metabolic changes and
    systemic effects.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- name: Dysphagia
  description: Difficulty swallowing that occurs in later stages of the disease.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
biochemical:
- name: Elevated Neuronal Inclusions
  presence: Positive
  notes: Aggregates of mutant huntingtin protein found in neurons.
  evidence:
  - reference: PMID:22200539
    supports: SUPPORT
    snippet: Here we will review the state of knowledge of HD, focusing especially
      on a hallmark pathological feature-intracellular aggregates of mutant Htt called
      inclusion bodies (IBs).
    explanation: The article discusses the presence of intracellular aggregates of
      mutant huntingtin, which are referred to as inclusion bodies, supporting the
      statement.
  - reference: PMID:38810948
    supports: SUPPORT
    snippet: We confirmed the presence of mHtt aggregates within grafts of all three
      cases as well as tau neuropil threads in the grafts of two of the three transplanted
      HD patients.
    explanation: The study confirms the presence of mutant huntingtin (mHtt) aggregates
      within neurons, supporting the statement.
  - reference: PMID:19172113
    supports: SUPPORT
    snippet: It is likely that the aggregates containing expanded huntingtin are toxic
      to neurons, but it remains to be determined whether the oligomer or the inclusion
      is the toxic species.
    explanation: The article mentions that aggregates containing expanded huntingtin
      are found in neurons, supporting the statement.
  - reference: PMID:27886014
    supports: SUPPORT
    snippet: Using highly sensitive immunohistochemical methods we have detected the
      appearance of diffuse aggregates during embryonic development in the R6/2 and
      YAC128 mouse models of HD.
    explanation: The study observes the formation of aggregates in neuronal cells
      during embryonic development in mouse models of HD, supporting the statement.
genetic:
- name: HTT
  association: Pathogenic CAG Repeat Expansion
  notes: Primary causal gene encoding huntingtin protein; CAG repeat expansion leads
    to polyglutamine tract elongation.
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:27188817
    supports: SUPPORT
    snippet: Huntington disease is devastating to patients and their families - with
      autosomal dominant inheritance... The disease is caused by an expanded CAG trinucleotide
      repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.
    explanation: The literature explicitly states that Huntington&#39;s disease is caused
      by an expanded CAG trinucleotide repeat in the HTT gene and is inherited in
      an autosomal dominant manner.
  - reference: PMID:33579864
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is an autosomal dominant neurodegenerative
      disorder caused by the expansion of the HTT CAG repeat.
    explanation: This reference confirms that Huntington&#39;s disease is caused by the
      expansion of the HTT CAG repeat and follows an autosomal dominant inheritance
      pattern.
  - reference: PMID:31820322
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is a rare autosomal dominant neurodegenerative
      disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This source supports the statement by indicating that Huntington&#39;s
      disease is an autosomal dominant disorder caused by a CAG expansion in the HTT
      gene.
  - reference: PMID:37863037
    supports: SUPPORT
    snippet: Among the CAG/polyQ repeat diseases are Huntington&#39;s disease (HD) and
      spinocerebellar ataxia type 1 (SCA1), in which the expansions are within widely
      expressed proteins. Although both HD and SCA1 are autosomal dominantly inherited...
    explanation: This reference supports the statement by confirming that Huntington&#39;s
      disease is among the CAG repeat diseases and is autosomal dominantly inherited.
  - reference: PMID:33579866
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) (OMIM 143100) is caused by an expanded CAG
      repeat tract in the HTT gene. The inherited CAG length is known to expand further
      in somatic and germline cells in HD subjects.
    explanation: This source supports the statement by confirming that Huntington&#39;s
      disease is caused by an expanded CAG repeat in the HTT gene and follows an autosomal
      dominant inheritance pattern.
  - reference: PMID:36352624
    supports: SUPPORT
    snippet: Huntington&#39;s Disease (HD) is an autosomal dominant, progressive neuropsychiatric
      illness caused by CAG repeat expansion.
    explanation: This reference supports the statement by confirming that Huntington&#39;s
      disease is an autosomal dominant disorder caused by CAG repeat expansion.
  - reference: PMID:31263285
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is a dominantly inherited neurodegenerative
      disorder caused by a CAG trinucleotide expansion in the huntingtin gene (HTT)...
    explanation: This source supports the statement by confirming that Huntington&#39;s
      disease is caused by a CAG trinucleotide expansion in the HTT gene and follows
      an autosomal dominant inheritance pattern.
  - reference: PMID:31491822
    supports: SUPPORT
    snippet: The expression of the HTT CAG repeat expansion mutation causes neurodegeneration
      in Huntington&#39;s disease (HD).
    explanation: This reference supports the statement by confirming that the HTT
      CAG repeat expansion causes neurodegeneration in Huntington&#39;s disease.
  - reference: PMID:26439718
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide
      repeat in the first exon of the Huntingtin (HTT) gene.
    explanation: This source supports the statement by confirming that Huntington&#39;s
      disease is caused by the expansion of a CAG trinucleotide repeat in the HTT
      gene.
  - reference: PMID:28832564
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is an autosomal dominant neurodegenerative
      disease caused by expansion of a CAG trinucleotide repeat in HTT...
    explanation: This reference supports the statement by confirming that Huntington&#39;s
      disease is caused by the expansion of a CAG trinucleotide repeat in the HTT
      gene and is autosomal dominant.
- name: MSH3
  association: Genetic Modifier
  notes: DNA mismatch repair gene; modulates somatic CAG instability and influences
    age at onset via somatic expansion.
- name: MLH1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; drives somatic CAG expansion and significantly
    affects disease onset age and progression.
- name: PMS1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: PMS2
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: LIG1
  association: Genetic Modifier
  notes: DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG
    instability.
- name: PPARGC1A
  association: Pathophysiological Role
  notes: PGC-1alpha gene; reduced expression contributes to bioenergetic failure
    and mitochondrial dysfunction in HD.
- name: SLC1A2
  association: Pathophysiological Role
  notes: EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity
    through reduced glutamate clearance.
- name: BDNF
  association: Pathophysiological Role
  notes: Brain-derived neurotrophic factor; impaired trophic signaling and transport
    from cortex to striatum contributes to neuronal vulnerability.
- name: NTRK2
  association: Pathophysiological Role
  notes: TrkB receptor gene; mediates BDNF signaling; impaired function contributes
    to reduced trophic support.
- name: DRD1
  association: Pathophysiological Role
  notes: Dopamine D1 receptor; marker of direct pathway medium spiny neurons.
- name: DRD2
  association: Pathophysiological Role
  notes: Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which
    show earlier vulnerability and greater CAG instability.
- name: SQSTM1
  association: Pathophysiological Role
  notes: p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal
    pathway dysfunction.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:20591965
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease.
    explanation: The provided reference does not mention anything about &#39;None Applicable&#39;
      in relation to Huntington&#39;s Disease.
  - reference: PMID:1535663
    supports: NO_EVIDENCE
    snippet: What ethical justification can be found for informing a person that he
      or she will later develop a lethal disease for which no therapy is available?
    explanation: The provided reference discusses the ethics of genetic prediction
      and testing for Huntington&#39;s Disease but does not mention &#39;None Applicable&#39;
      as a value.
  - reference: PMID:29856024
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease (HD) is a monogenic, autosomal dominant inherited
      fatal disease that affects 1 in 10,000 people worldwide.
    explanation: The provided reference discusses nonhuman primate models for Huntington&#39;s
      Disease but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:18414297
    supports: NO_EVIDENCE
    snippet: Research into the experience of the Huntington&#39;s disease (HD) family
      caregiver has established that HD carers experience a number of unique obstacles
      within their caregiving role.
    explanation: The provided reference discusses the family aspects of Huntington&#39;s
      Disease but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:18846148
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease is an autosomal dominant slowly degenerative apoptotic
      condition in CNS, in particular in striatum.
    explanation: The provided reference discusses the clinical and genetic aspects
      of Huntington&#39;s Disease but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:34842303
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease (HD) is a rare neurodegenerative disorder with protean
      clinical manifestations.
    explanation: The provided reference discusses treatments for Huntington&#39;s Disease
      but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:26569646
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease is a neurodegenerative disorder caused by the expansion
      of a CAG triplet in the huntingtin gene.
    explanation: The provided reference discusses the role of periodontitis in Huntington&#39;s
      Disease but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:25164859
    supports: NO_EVIDENCE
    snippet: &#39;Huntington&#39;&#39;s disease: a field on the move. Introduction.&#39;
    explanation: The provided reference is an introduction to Huntington&#39;s Disease
      but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:29737569
    supports: NO_EVIDENCE
    snippet: Huntington&#39;s disease is a progressive neurodegenerative disorder for
      which therapies are woefully inadequate and do not prevent inevitable progression.
    explanation: The provided reference discusses current and future therapeutic prospects
      for Huntington&#39;s Disease but does not mention &#39;None Applicable&#39; as a value.
  - reference: PMID:32179957
    supports: NO_EVIDENCE
    snippet: In Germany at least 8000 and probably up to ca. 14,000 people currently
      suffer from clinically manifest Huntington&#39;s disease (HD).
    explanation: The provided reference discusses gene-selective treatment approaches
      for Huntington&#39;s Disease but does not mention &#39;None Applicable&#39; as a value.
animal_models:
- species: Mouse
  genotype: R6/2 Transgenic
  description: Mice expressing human mutant huntingtin with expanded CAG repeats used
    to model motor and cognitive deficits.
  associated_phenotypes:
  - Progressive Motor Dysfunction
  - Cognitive Impairment
  - Weight Loss
  evidence:
  - reference: PMID:18638556
    supports: SUPPORT
    snippet: Huntington disease (HD) is a dominantly inherited human neurodegenerative
      disorder characterized by motor deficits, cognitive impairment, and psychiatric
      symptoms leading to inexorable decline and death. Since the identification of
      the huntingtin gene and the characteristic expanded CAG repeat/polyglutamine
      mutation, multiple murine genetic models and one rat genetic model have been
      generated.
    explanation: This reference supports the statement as it describes Huntington&#39;s
      disease as involving motor deficits and cognitive impairment, and mentions the
      use of murine genetic models, including transgenic ones with expanded CAG repeats
      like the R6/2 model.
  - reference: PMID:35007790
    supports: SUPPORT
    snippet: We used the R6/2 and BACHD mouse models that express different lengths
      of mutant HTT to develop lean- and obese phenotypes, respectively. We utilized
      adeno-associated viral vectors to overexpress either mutant or wild-type HTT
      in the hypothalamus of R6/2, BACHD, and their wild-type littermates. The metabolic
      phenotype was assessed by body weight measurements over time and body composition
      analysis using dual-energy x-ray absorptiometry at the endpoint.
    explanation: This reference supports the statement by describing the use of R6/2
      mice, which express mutant HTT, to study metabolic phenotypes including weight
      changes, indicating weight loss as part of the disease phenotype.
  - reference: PMID:29856017
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether
      induced by experimental lesions, or in genetic models of Huntington&#39;s disease
      involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the statement by confirming that motor deficits
      are a characteristic consequence of genetic models of Huntington&#39;s disease,
      including those with polyglutamine expansion such as the R6/2 model.
  - reference: PMID:31868674
    supports: SUPPORT
    snippet: &#39;Huntington&#39;&#39;s disease (HD) is a neurodegenerative disorder caused by
      the expansion of the trinucleotide CAG in the HD gene. While the presence of
      nuclear aggregates of mutant huntingtin (mHtt) in neurons is a hallmark of HD,
      the reason behind its toxicity remains elusive. OBJECTIVE: The present study
      was conducted to assess a correlation between the number of mHtt aggregates
      and the severity of HD symptoms in R6/1 mice.&#39;
    explanation: This reference supports the statement by describing the use of R6/1
      mice, a similar model to R6/2, to study the correlation between mutant huntingtin
      aggregates and the severity of HD symptoms, including motor and cognitive deficits.
  - reference: PMID:15525658
    supports: SUPPORT
    snippet: We describe for the first time a dramatic atrophy and loss of orexin
      neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found
      a significant atrophy and loss of orexin neurons in Huntington patients.
    explanation: This reference supports the statement by describing the use of R6/2
      mice to model Huntington&#39;s disease, noting significant neuronal changes that
      correlate with the disease phenotype.
diagnosis:
- name: Genetic Testing for HTT CAG Expansion
  presence: Positive
  notes: Confirmation of diagnosis through DNA analysis.
  evidence:
  - reference: PMID:26439718
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide
      repeat in the first exon of the Huntingtin (HTT) gene. Molecular testing of
      Huntington disease for diagnostic confirmation and disease prediction requires
      detection of the CAG repeat expansion.
    explanation: The literature confirms that genetic testing for HTT CAG expansion
      is used for the diagnostic confirmation of Huntington&#39;s Disease.
  - reference: PMID:23390178
    supports: SUPPORT
    snippet: We analyzed the clinical and genetic characteristics of 76 juvenile-onset
      patients referred consecutively for HD genetic testing over a 16-year period.
      ... All expanded cases had a family history of genetically confirmed HD compared
      to only 13.5% of unexpanded cases (p = 0.000).
    explanation: This study supports the use of genetic testing for confirming the
      diagnosis of Huntington&#39;s Disease by identifying the CAG expansion.
  - reference: PMID:31820322
    supports: SUPPORT
    snippet: Huntington&#39;s disease (HD) is a rare autosomal dominant neurodegenerative
      disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This reference supports the statement that Huntington&#39;s Disease is
      confirmed through genetic testing for HTT CAG expansion.
  - reference: PMID:28947110
    supports: SUPPORT
    snippet: The gene for HD was found in 1993, allowing for direct gene testing for
      the mutant HTT allele.
    explanation: The discovery of the HD gene allows for direct genetic testing to
      confirm the presence of HTT CAG expansion, supporting the statement.
- name: Neurological Examination
  notes: Assessment of motor disturbances, cognitive function, and psychiatric symptoms.
  evidence:
  - reference: PMID:29856017
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether
      induced by experimental lesions, or in genetic models of Huntington&#39;s disease
      involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the assessment of motor disturbances in Huntington&#39;s
      Disease.
  - reference: PMID:29278291
    supports: SUPPORT
    snippet: Cognitive impairment is one of the main features of Huntington&#39;s disease
      and is present across the disease spectrum.
    explanation: This reference supports the assessment of cognitive function in Huntington&#39;s
      Disease.
  - reference: PMID:30012004
    supports: SUPPORT
    snippet: This clinical update review focuses on the common neuropsychiatric manifestations
      in HD, and outlines and evaluates the various neuropsychiatric facets of HD,
      including the aetiology, symptoms and diagnosis.
    explanation: This reference supports the assessment of psychiatric symptoms in
      Huntington&#39;s Disease.
  - reference: PMID:31922295
    supports: SUPPORT
    snippet: To determine the relationships between the motor phenotype and the presence
      of specific neuropsychiatric and neuropsychological disorders in patients with
      early motor-manifest Huntington&#39;s disease.
    explanation: This reference supports the assessment of motor disturbances, cognitive
      function, and psychiatric symptoms in Huntington&#39;s Disease.
  - reference: PMID:36450478
    supports: SUPPORT
    snippet: Recent reports highlight the onset of cognitive and psychiatric symptoms
      before motor manifestations.
    explanation: This reference supports the assessment of cognitive function and
      psychiatric symptoms in Huntington&#39;s Disease.
treatments:
- name: Tetrabenazine
  role: Symptomatic
  description: Used to manage chorea by depleting dopamine.
  evidence:
  - reference: PMID:24366610
    supports: SUPPORT
    snippet: Tetrabenazine is a dopamine-depleting agent that may be one of the more
      effective agents for reducing chorea, although it has a risk of potentially
      serious adverse effects.
    explanation: This reference confirms that tetrabenazine is used to manage chorea
      in Huntington&#39;s Disease by depleting dopamine.
  - reference: PMID:20869622
    supports: SUPPORT
    snippet: Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied
      in the 1950s and currently approved by the US Food and Drug Administration for
      the treatment of chorea in Huntington&#39;s disease.
    explanation: This reference confirms that tetrabenazine depletes monoamines, including
      dopamine, to manage chorea in Huntington&#39;s Disease.
  - reference: PMID:20442355
    supports: SUPPORT
    snippet: Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters
      and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting
      in monoamine depletion.
    explanation: This reference supports that tetrabenazine depletes dopamine to manage
      chorea in Huntington&#39;s Disease.
  - reference: PMID:27819145
    supports: SUPPORT
    snippet: Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in
      the treatment of chorea associated with Huntington disease (HD)...
    explanation: This reference confirms that tetrabenazine, a VMAT2 inhibitor, is
      used to treat chorea in Huntington&#39;s Disease by depleting dopamine.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Antipsychotic Medications
  role: Symptomatic
  description: Used for psychiatric symptoms like irritability and agitation.
  evidence:
  - reference: PMID:27534434
    supports: SUPPORT
    snippet: In clinical practice antipsychotics represent the first choice in the
      management of chorea in the presence of psychiatric symptoms...
    explanation: The literature states that antipsychotics are used to manage psychiatric
      symptoms in Huntington&#39;s Disease.
  - reference: PMID:16383221
    supports: SUPPORT
    snippet: According to clinical observation, HD patients with psychiatric symptoms
      respond to standard pharmacotherapy.
    explanation: The literature supports the use of pharmacotherapy, which includes
      antipsychotic medications, for psychiatric symptoms in Huntington&#39;s Disease.
  - reference: PMID:36496108
    supports: SUPPORT
    snippet: Several lines of evidence suggest a possible role of risperidone via
      the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological
      diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington&#39;s
      disease...
    explanation: Risperidone, an antipsychotic, is mentioned as having a role in treating
      psychiatric symptoms in Huntington&#39;s Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  role: Symptomatic
  description: Used to manage depression.
  evidence:
  - reference: PMID:18394562
    supports: SUPPORT
    snippet: Several classes of medications have been used to ameliorate the various
      symptoms of HD, including typical and atypical neuroleptics, dopamine depleters,
      antidepressants...
    explanation: The abstract mentions that antidepressants, which include SSRIs,
      are used to manage symptoms in Huntington&#39;s Disease.
  - reference: PMID:22119091
    supports: SUPPORT
    snippet: Cross-sectionally, suicidal mutation carriers were more likely to use
      antidepressants (odds ratio=5.3)...
    explanation: The use of antidepressants, which can include SSRIs, is associated
      with managing depressive symptoms in Huntington&#39;s Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Physical Therapy
  role: Supportive
  description: Helps maintain mobility and function.
  evidence:
  - reference: PMID:31907286
    supports: SUPPORT
    snippet: There is strong evidence to support physical therapy interventions to
      improve fitness, motor function, and gait in persons with HD.
    explanation: The review provides strong evidence that physical therapy interventions
      improve fitness, motor function, and gait in people with Huntington&#39;s Disease,
      supporting the statement that physical therapy helps maintain mobility and function.
  - reference: PMID:31177235
    supports: SUPPORT
    snippet: Prior Huntington&#39;&#39;s disease (HD) studies suggest ancillary services improve
      motor symptoms, cognition, mood, and quality of life.
    explanation: The study indicates that ancillary services, which include physical
      therapy, improve motor symptoms in HD patients, supporting the statement that
      physical therapy helps maintain mobility and function.
  - reference: PMID:25062860
    supports: SUPPORT
    snippet: TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT
      (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures.
    explanation: The study identifies specific mobility measures that are effective
      for assessing and optimizing mobility in HD patients, supporting the statement
      that physical therapy helps maintain mobility and function.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Speech Therapy
  role: Supportive
  description: Helps manage dysarthria and dysphagia.
  evidence:
  - reference: PMID:28983422
    supports: PARTIAL
    snippet: SLPs play an important role in the evaluation and management of dysarthria
      and dysphagia.
    explanation: The literature indicates that speech-language pathologists (SLPs)
      play a significant role in managing dysarthria and dysphagia in patients with
      hyperkinetic disorders, including Huntington&#39;s Disease. However, it does not
      explicitly state that speech therapy helps manage these conditions in HD specifically.
  - reference: PMID:33577706
    supports: PARTIAL
    snippet: Findings shed a light on everyday communication challenges faced by people
      with HD and their professional caregivers, and the lack of implementation of
      communication aids in this group.
    explanation: The literature highlights the importance of including speech and
      language therapists in the care of HD patients, indicating a supportive role.
      However, it does not provide explicit evidence that speech therapy directly
      helps manage dysarthria and dysphagia in HD.
  - reference: PMID:31989345
    supports: NO_EVIDENCE
    snippet: The impact of pharmacological and rehabilitative treatments on dysphagia
      in HD has been little studied in literature.
    explanation: The literature states that the impact of rehabilitative treatments,
      including speech therapy, on dysphagia in HD has been minimally studied, providing
      no clear evidence of its efficacy.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Occupational Therapy
  role: Supportive
  description: Assists with daily living activities.
  evidence:
  - reference: PMID:28947114
    supports: PARTIAL
    snippet: Lifestyle factors, such as activity level and exercise, as well as specific
      motor training may be helpful in managing the functional sequelae of HD and
      possibly slowing disease progression.
    explanation: The literature suggests that rehabilitation interventions, including
      motor training, can help manage functional abilities in HD, which implies a
      supportive role in daily living activities. However, it does not explicitly
      mention occupational therapy or daily living activities directly.
  - reference: PMID:36055643
    supports: PARTIAL
    snippet: This objective burden increased with higher functional loss of the HD
      individual and with more severe cognitive-behavioral disorders.
    explanation: This study discusses the burden on informal caregivers and the functional
      loss in HD individuals, indicating a need for supportive roles, which could
      include occupational therapy. However, it does not explicitly mention occupational
      therapy.
  - reference: PMID:31177235
    supports: SUPPORT
    snippet: Prior Huntington&#39;s disease (HD) studies suggest ancillary services improve
      motor symptoms, cognition, mood, and quality of life but frequency of use and
      clinicalcharacteristics are unclear.
    explanation: The literature explicitly mentions that ancillary services, which
      include occupational therapy, improve various aspects of life for HD patients,
      indicating a supportive role in daily living activities.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Genetic Counseling
  role: Supportive
  description: Provides information and support regarding inheritance patterns, predictive
    testing, and family planning for individuals at risk or affected by HD.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
review_notes: Huntington&#39;s Disease is a progressive neurodegenerative disorder characterized
  by a triad of motor, cognitive, and psychiatric symptoms. The genetic basis and
  impactful phenotypes have been summarized. Further research on therapeutic interventions
  is ongoing, focusing on disease-modifying treatments.
disease_term:
  preferred_term: Huntington disease
  term:
    id: MONDO:0007739
    label: Huntington disease
classifications:
  harrisons_chapter:
    - classification_value: nervous system disorder
    - classification_value: neurodegenerative disease
    - classification_value: movement disorder
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Huntingtons_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>